EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.

Abstract excerpt

INTRODUCTION: KRAS is one of the most commonly occurring mutated oncogene in human cancers. Development of KRAS G12C or G12D inhibitors exhibit promising clinical activities, but patients harboring other hotspot KRAS mutations cannot benefit from those strategies. Recent development in pan-RAS inhibitors have broad therapeutic implications and merit clinical investigation. However, intrinsic and acquired drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Proliferation
• Share to CRISPR-Cas Systems
• Share to Drug Resistance, Neoplasm